中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2011年
6期
385-388
,共4页
董秀娟%赵晓武%马红霞%吴书一%赛亚
董秀娟%趙曉武%馬紅霞%吳書一%賽亞
동수연%조효무%마홍하%오서일%새아
红斑狼疮,系统性%造血干细胞%移植
紅斑狼瘡,繫統性%造血榦細胞%移植
홍반랑창,계통성%조혈간세포%이식
Lupus erythematosus,systemic%Hematopoietic stem cells%Transplantation
目的 探讨自体造血干细胞移植治疗系统性红斑狼疮(SLE)的远期疗效.方法 分析48例接受自体造血干细胞移植的SLE患者于移植后的随访情况,自诊断时间计算,病程均超过10年.其中24例为CD34+细胞纯化移植,24例非CD34瑚胞纯化移植.采用驴榆验进行统计分析.结果 死亡5例,移植相关死亡4例,其中3例为CD34+移植.自诊断病程超过10年的生存率为90%(43/48).可评价的43例中,复发7例,6例为非CD34+细胞纯化移植,1例为CD34+细胞纯化移植.CD34+细胞纯化移植复发率为5%(1/21),非CD34+细胞纯化移植复发率为27%(6/22),2组问复发率差异有统计学意义(x2=3.995,P=0.046).随访中,8例上大学,26例恢复正常工作与生活,其中4例生育子女.结论 自体造血干细胞移植联合抗人胸腺球蛋白(ATG)治疗SLE的远期疗效确切,CD34+植复发率低于非CD34+移植,尤其是SLE患者移植后生活质量好于传统治疗.
目的 探討自體造血榦細胞移植治療繫統性紅斑狼瘡(SLE)的遠期療效.方法 分析48例接受自體造血榦細胞移植的SLE患者于移植後的隨訪情況,自診斷時間計算,病程均超過10年.其中24例為CD34+細胞純化移植,24例非CD34瑚胞純化移植.採用驢榆驗進行統計分析.結果 死亡5例,移植相關死亡4例,其中3例為CD34+移植.自診斷病程超過10年的生存率為90%(43/48).可評價的43例中,複髮7例,6例為非CD34+細胞純化移植,1例為CD34+細胞純化移植.CD34+細胞純化移植複髮率為5%(1/21),非CD34+細胞純化移植複髮率為27%(6/22),2組問複髮率差異有統計學意義(x2=3.995,P=0.046).隨訪中,8例上大學,26例恢複正常工作與生活,其中4例生育子女.結論 自體造血榦細胞移植聯閤抗人胸腺毬蛋白(ATG)治療SLE的遠期療效確切,CD34+植複髮率低于非CD34+移植,尤其是SLE患者移植後生活質量好于傳統治療.
목적 탐토자체조혈간세포이식치료계통성홍반랑창(SLE)적원기료효.방법 분석48례접수자체조혈간세포이식적SLE환자우이식후적수방정황,자진단시간계산,병정균초과10년.기중24례위CD34+세포순화이식,24례비CD34호포순화이식.채용려유험진행통계분석.결과 사망5례,이식상관사망4례,기중3례위CD34+이식.자진단병정초과10년적생존솔위90%(43/48).가평개적43례중,복발7례,6례위비CD34+세포순화이식,1례위CD34+세포순화이식.CD34+세포순화이식복발솔위5%(1/21),비CD34+세포순화이식복발솔위27%(6/22),2조문복발솔차이유통계학의의(x2=3.995,P=0.046).수방중,8례상대학,26례회복정상공작여생활,기중4례생육자녀.결론 자체조혈간세포이식연합항인흉선구단백(ATG)치료SLE적원기료효학절,CD34+식복발솔저우비CD34+이식,우기시SLE환자이식후생활질량호우전통치료.
Objective To investigate the long-term efficacy of autologous stem cell transplantation for systemic lupus erythematosus (SLE). Methods Long-term follow up of 48 SLE patients with autologous stem cell transplantation were studied. All patients were followed up for 10 years. Among the patients, 24 cases were treated with purified CD34+ cells transplantation and 24 cases were treated with non-CD34+ cell transplantation. Comparison between groups was performed by x2 test. Results Among 5 dead patients, 4 died of transplantation related complications including 3 cases treated with CD34+ transplantion. The survival rate of those patients with more than 10 years duration of lupus was 90%(43/48). Among 43 patients, 7 had disease flare, 6 were treated with non-CD34+ cell transplantation. Eight patients went to college, 26 returned to normal life and 4 of them had children. Conclusion The long-term effect of SLE treated with autologous hematopoietic stem cell transplantation and anti-thymocyte globulin (ATG) is good. The recurrence of CD34+ transplant patients is lower than those treated with non-CD34+ transplantation. The quality of life in SLE patients treated with transplantation is better than those treated with conventional therapy.